Understanding the Market | QYUNS-B rose over 11% during the session, its QX031N licensed to Roche; institutions say this transaction has certain rarity
I'm PortAI, I can summarize articles.
QYUNS-B's stock price rose over 11% during intraday trading, and as of the time of writing, it has increased by 4.78%, reaching HKD 22.82, with a transaction volume of HKD 12.2938 million. The company has reached a global exclusive collaboration and licensing agreement with Roche, involving the long-acting self-immune dual antibody QX031N. QYUNS will receive a USD 75 million upfront payment and up to USD 995 million in milestone payments. Zhongyou Securities pointed out that this transaction demonstrates the clinical value and market potential of QX031N, which possesses a certain degree of rarity
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments